For the millions of women told their mammograms are limited by dense breast tissue, the choice of supplemental screening technology is not merely procedural — it shapes how often they face unnecessary callbacks, anxiety-inducing follow-ups, and potentially unneeded biopsies. A large real-world comparison now quantifies meaningful performance differences between two ultrasound approaches used alongside standard mammography.
Drawing on over 25,000 supplemental ultrasound examinations conducted at 27 radiology facilities across three Breast Cancer Surveillance Consortium registries between 2017 and 2020, investigators compared automated breast ultrasound (ABUS) against conventional handheld ultrasound (HHUS) in women with confirmed dense breast tissue. ABUS was associated with a substantially lower abnormal interpretation rate — 14.9% versus 19.2% — and a dramatically reduced short-interval follow-up recommendation rate of 3.0% compared to 14.6% for HHUS. False-positive initial assessment rates similarly favored ABUS. Critically, no meaningful differences emerged in biopsy recommendation rates, positive predictive values, or cancer detection rates, suggesting ABUS reduces noise without sacrificing diagnostic sensitivity.
This finding carries important nuance that the headline numbers alone cannot convey. The dramatic reduction in short-interval follow-up — nearly a fivefold difference — reflects a structural advantage of ABUS: standardized image acquisition reduces the operator-dependent variability inherent in handheld scanning, where the skill and interpretive habits of individual sonographers can inflate recall rates. That said, this is observational data, not a randomized trial, meaning patient selection differences across facilities could partly explain the gaps. ABUS typically requires longer acquisition and reading time and may be less effective for small or irregular breast geometries. The study's pre-2021 timeframe also predates recent advances in AI-assisted HHUS interpretation that are beginning to narrow reproducibility gaps. Still, for dense-breast screening programs seeking to minimize false-positive burden at scale, this evidence meaningfully supports ABUS as a candidate modality — particularly in high-volume settings where operator consistency is difficult to guarantee.